Literature DB >> 23745568

Severity of hydronephrosis correlates with tumour invasiveness and urinary bladder recurrence of ureteric cancer.

Hao Lun Luo1, Chih Hsiung Kang, Yen Ta Chen, Yao Chi Chuang, Wei Ching Lee, Yuan Tso Cheng, Po Hui Chiang.   

Abstract

OBJECTIVES: To explore the prognostic role of hydronephrosis grade in patients with pure ureteric cancer. PATIENTS AND METHODS: The study included 162 patients with pure ureteric cancer who were treated between January 2005 and December 2010 at a single tertiary referral centre. The association between hydronephrosis grade with pathological findings and oncological outcomes was assessed using multivariate Cox regression analysis.
RESULTS: Hydronephrosis grade >2 was independently associated with non-organ-confined ureteric cancer (P = 0.003). Hydronephrosis grade <2 was highly prevalent in organ-confined disease. Hydronephrosis grade >2 and bladder cancer history independently predict bladder cancer recurrence (P = 0.021 and P = 0.002, respectively) Hydronephrosis of grade >2 was found to be associated with local and distant recurrence only in univariate analysis; non-organ-confined pathology independently predicted local and distant oncological failure (P ≤ 0.001 and P = 0.002, respectively).
CONCLUSIONS: Hydronephrosis grade >2 is associated with non-organ-confined ureteric cancer and with bladder cancer recurrence. Non-organ-confined pathology is still the most important predictor for local and distant oncological failure.
© 2013 BJU International.

Entities:  

Keywords:  bladder recurrence; hydronephrosis; oncologic outcome; organ confined; predictive factor; ureteric cancer

Mesh:

Year:  2013        PMID: 23745568     DOI: 10.1111/bju.12157

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  6 in total

1.  The Value of Preoperative Local Symptoms in Prognosis of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy: A Retrospective, Multicenter Cohort Study.

Authors:  Hsin-Chih Yeh; Chao-Hsiang Chang; Jen-Kai Fang; I-Hsuan Alan Chen; Jen-Tai Lin; Jian-Hua Hong; Chao-Yuan Huang; Shian-Shiang Wang; Chuan-Shu Chen; Chi-Wen Lo; Chih-Chin Yu; Jen-Shu Tseng; Wun-Rong Lin; Yeong-Chin Jou; Ian-Seng Cheong; Yuan-Hong Jiang; Chung-You Tsai; Thomas Y Hsueh; Yung-Tai Chen; Hsu-Che Huang; Yao-Chou Tsai; Wei-Yu Lin; Chia-Chang Wu; Po-Hung Lin; Te-Wei Lin; Wen-Jeng Wu
Journal:  Front Oncol       Date:  2022-06-02       Impact factor: 5.738

2.  Concurrent Preoperative Presence of Hydronephrosis and Flank Pain Independently Predicts Worse Outcome of Upper Tract Urothelial Carcinoma.

Authors:  Hsin-Chih Yeh; Hau-Chern Jan; Wen-Jeng Wu; Ching-Chia Li; Wei-Ming Li; Hung-Lung Ke; Shu-Pin Huang; Chia-Chu Liu; Yung-Chin Lee; Sheau-Fang Yang; Peir-In Liang; Chun-Nung Huang
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

3.  Prediction of high-grade ureteral urothelial carcinoma on CT urography.

Authors:  Hwang Sung Tae; Sung Deuk Jae; Yang Kyung Sook; Sim Ki Choon; Han Na Yeon; Park Beom Jin; Kim Min Ju; Cho Sung Bum
Journal:  Br J Radiol       Date:  2017-08-22       Impact factor: 3.039

4.  Prognostic impact of perirenal fat stranding on oncologic outcomes in ureteral urothelial carcinoma.

Authors:  Jae Wook Chung; Jun Nyung Lee; Kyong Min Park; Kyeong Hyeon Byeon; Hyejin Cheon; Yun Sok Ha; Seock Hwan Choi; Bum Soo Kim; Tae Hwan Kim; Eun Sang Yoo; Tae Gyun Kwon; Hyun Tae Kim
Journal:  Investig Clin Urol       Date:  2020-12-09

5.  Clinical and prognostic value of preoperative hydronephrosis in upper tract urothelial carcinoma: a systematic review and meta-analysis.

Authors:  Yuejun Tian; Yuwen Gong; Yangyang Pang; Zhiping Wang; Mei Hong
Journal:  PeerJ       Date:  2016-06-21       Impact factor: 2.984

6.  Preoperative hydronephrosis predicts adverse pathological features and postoperative survival in patients with high-grade upper tract urothelial carcinoma.

Authors:  Subo Qian; Chengcai Liang; Yu Ding; Chen Wang; Haibo Shen
Journal:  Int Braz J Urol       Date:  2021 Jan-Feb       Impact factor: 1.541

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.